Fredrickson David Paul 4

What Happened

• Director David Paul Fredrickson was issued 2,492 shares of Caris Life Sciences common stock on Feb 26, 2026, at an effective price of $20.06 per share, with a total value of $49,990. The transaction is reported on a Form 4 as an award/acquisition (code A).

Key Details

• Transaction date: 2026-02-26; reported on Form 4 filed 2026-02-27.
• Shares/price/value: 2,492 shares at $20.06 per share, total ≈ $49,990.
• Transaction type: Award/Grant (A) — shares issued in lieu of cash compensation for 2025 board retainer fees (see footnote F1).
• Footnote F1: Shares were issued in lieu of cash; the share count was determined by dividing the cash retainer by the 10-trading-day average daily VWAP through and including Feb 25, 2026.
• Shares owned after the transaction: Not reported in this filing.
• Timeliness: Filing appears timely (transaction 2/26/2026; Form 4 filed 2/27/2026).

Context

• This issuance represents compensation rather than an open-market purchase or sale, so it is routine corporate compensation and does not necessarily indicate the director’s market view. The award simply converts the board retainer that would have been paid in cash into shares based on a recent VWAP.